Experience
Boston Heart Diagnostics Corp.
Health Diagnostic Laboratory, Inc,
Finnegan client Health Diagnostic Laboratory, Inc. (HDL) served Boston Health Diagnostics Corporation with a complaint in the Eastern District of Virginia, alleging infringement of its patent directed to methods of predicting the risk of developing diabetes based on a model HDL developed using unique biomarker combinations. Boston Heart immediately petitioned the Patent Trial and Appeal Board (PTAB) to institute an inter partes review (IPR) challenging HDL’s asserted claims as anticipated and obvious in view of several prior art references. Finnegan secured a non-institution decision for HDL through arguments raised in its patent owner’s preliminary response that Boston Heart failed to demonstrate the prior art taught the diagnostic model using the claimed biomarker panels. The PTAB denied institution on all grounds, concluding that the petition failed to adequately explain how the cited references disclose the model as claimed.
Boston Heart Diagnostics Corp. v. Health Diagnostic Laboratory, Inc,, IPR2015-00557, PTAB, Judges Elluru, Franklin, Paulraj
Boston Heart Diagnostics Corp. v. Health Diagnostic Laboratories
Health Diagnostic Laboratories
Finnegan secures a non-institution decision at the PTAB for client iFLY Holdings LLC
iFLY Holdings LLC
Siemens Healthcare Diagnostics Inc. v. Radiometer Medical ApS
Radiometer Medical ApS
Finnegan client AbbVie secures non-institution decisions for Humira® patents
AbbVie Biotechnology, Ltd
Sequenom, Inc. et al
Auris Health, Inc. v. Intuitive Surgical Operations
Intuitive Surgical Operations
AbbVie secures four non-institution decisions for Humira® patent
AbbVie Biotechnology, Ltd.
Finnegan goes three-for-three in IPR non-institution decisions for client inMusic
inMusic Brands, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.